- Home
- IOVA vs NEA Comparison
IOVA vs NEA Comparison
Compare IOVA & NEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IOVA | NEA |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 3.5B |
| IPO Year | 2008 | 2002 |
Fundamental Metrics
Financial Performance| Metric | IOVA | NEA |
|---|---|---|
| Price | $3.33 | $10.98 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $9.11 | N/A |
| AVG Volume (30 Days) | ★ 15.6M | 941.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.55 | N/A |
| Revenue Next Year | $37.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $10.00 |
| 52 Week High | $5.63 | $11.90 |
Technical Indicators
Market Signals| Indicator | IOVA | NEA |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 25.60 |
| Support Level | $2.02 | $10.60 |
| Resistance Level | $4.34 | $11.00 |
| Average True Range (ATR) | 0.33 | 0.12 |
| MACD | -0.14 | -0.07 |
| Stochastic Oscillator | 2.86 | 23.04 |
Price Performance
Historical ComparisonAbout IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.